Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Methotrexate and Chemoradiotherapy in Pediatric High-Grade Glioma
NCT00278278Phase 3Unknown
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Sep 2003
- Primary completion
- Mar 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate in glioma and diffuse intrinsic pontine glioma (DIPG) (2 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoint: Overall Survival at 5.5 years. Status: unknown.
02
Drugs
methotrexate
03
Conditions
gliomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT00278278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278278.